Abstract
Purpose: To observe the clinical efficacy of conbercept in the treatment of choroidal neovascularization (CNV) secondary to pathologic myopia. Methods: Retrospective analysis of 20 patients (24 eyes) with pathologic myopia choroidal neovascularization (PM-CNV) treated with intravitreal conbercept (0.5 mg). Primary outcomes included functional changes via multifocal electroretinogram (mfERG) and structural changes via central macular thickness (CRT). Results: BCVA improved significantly from baseline to 6 months ($P < 0.05$). CRT decreased from 308.50 μm to 220.96 μm. mfERG P1 amplitude improved from 40.71 to 55.67 nv/deg². CNV leakage disappeared in 83.3% of eyes. Conclusion: Intravitreal conbercept is safe and effective, improving both retinal morphology and function in PM-CNV.
Introduction
Pathologic Myopia (PM) is a major cause of global vision loss, especially in Asian populations. A critical complication is Choroidal Neovascularization (CNV), where abnormal blood vessels leak fluid or blood, causing rapid central vision impairment. This process is primarily driven by Vascular Endothelial Growth Factor (VEGF). Conbercept, a multi-target anti-VEGF fusion protein, binds VEGF-A, VEGF-B, and Placental Growth Factor (PlGF) with high affinity. This study evaluates whether conbercept can restore both the structural integrity and the electrical function of the retina.
Methods
This retrospective study analyzed 24 eyes from 20 patients with PM-CNV. All patients received intravitreal injections of 0.5 mg conbercept and were followed for at least six months. Assessment tools included:
- Best Corrected Visual Acuity (BCVA): Subjective vision measurement.
- Optical Coherence Tomography (OCT): Measurement of Central Macular Thickness (CRT).
- Fundus Fluorescein Angiography (FFA): Visualization of CNV lesion area and leakage.
- Multifocal Electroretinogram (mfERG): Objective measurement of foveal electrical response (P1 wave amplitude).
Results
The study found statistically significant improvements ($P < 0.05$) across all key metrics:
Visual and Structural Outcomes
BCVA improved from a baseline of 64.33 letters to 67.67 letters at 6 months. Concurrently, CRT decreased significantly from 308.50 μm to 220.96 μm, indicating a resolution of macular edema and restoration of retinal anatomy.
Functional Recovery
A key finding was the improvement in mfERG P1 response density, which rose from 40.71 nv/deg² to 55.67 nv/deg². This suggests that the retinal cells recovered physiological signaling capacity post-treatment, moving beyond mere structural improvement to true functional restoration.
CNV Resolution
After 6 months, CNV leakage completely disappeared in 83.3% of eyes, and the remaining 16.7% showed significant reduction in leakage area. No serious ocular or systemic adverse events were reported, confirming a high safety profile for the treatment.
Discussion and Conclusion
Conbercept's broad-spectrum inhibition (targeting VEGF-A, B, and PlGF) likely contributes to its robust efficacy in PM-CNV compared to single-target agents. Unlike studies focusing solely on anatomy, the inclusion of mfERG provides objective evidence of functional retinal recovery.
While limited by a small sample size and retrospective design, these results suggest that conbercept is a safe and effective treatment for PM-CNV, offering rapid and sustained improvements in both vision and retinal health. Future prospective, multi-center trials are warranted to further validate these findings and establish long-term protocols.
Summary updated